Please assess the completion status of the following clinical trial:

Trial Title: Dose-adjusted EPOCH-R in MYC Positive DLBCL

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Previously untreated MYC positive diffuse large B-cell lymphoma~* Age range 18-70 years old~* Eastern Cooperative Oncology Group performance status 0-2~* Life expectancy of more than 3 months~* Adequate organ function~Exclusion Criteria:~* Primary or secondary central nervous system involvement~* Previous serious cardiac disease~* History of other malignancies except cured basal cell carcinoma of skin and carcinoma in-situ of uterine cervix~* Pregnant or lactating women~* Serious uncontrolled diseases and intercurrent infection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- DA-EPOCH-R (Type: EXPERIMENTAL): rituximab 375mg/m2 IV day 0, etoposide 50mg/m2/d CIV days 1-4, doxorubicin 10mg/m2/d CIV days 1-4, vincristine 0.4mg/m2/d CIV days 1-4, cyclophosphamide 750mg/m2 IV day 5, prednisone 50mg PO days 1-5 twice per day

Based on this trial design, predict the completion outcome and termination type (if applicable).